Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
STIMULATION OF NONSPECIFIC IMMUNITY TO REDUCE THE RISK OF RECURRENT INFECTIONS IN CHILDREN ATTENDING DAY-CARE-CENTERS
Autore:
COLLET JP; DUCRUET T; KRAMER MS; HAGGERTY J; FLORET D; CHOMEL JJ; DURR F; AYMAND M; HONEGGER D; GILLET J; DEGUERRY M; LAMY D; MAUOUIT A; CHAIZE MA; FONVIEILLE AM; PORTEVIN B; DUCHIN MJ;
Indirizzi:
MCGILL UNIV,DEPT EPIDEMIOL,1020 PINE AVE W MONTREAL H3A 1A2 PQ CANADA UNITE PHARMACOL CLIN F-69424 LYON 03 FRANCE MCGILL UNIV,DEPT PEDIAT MONTREAL H3A 1A2 PQ CANADA HOP EDOUARD HERRIOT F-69003 LYON FRANCE UNIV LYONS 1,DEPT MICROBIOL F-69008 LYON FRANCE
Titolo Testata:
The Pediatric infectious disease journal
fascicolo: 8, volume: 12, anno: 1993,
pagine: 648 - 652
SICI:
0891-3668(1993)12:8<648:SONITR>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
OTITIS-MEDIA; BACTERIAL EXTRACT; EFFUSION;
Keywords:
RESPIRATORY INFECTIONS; GASTROENTERITIS; CHILD DAY CARE; IMMUNITY; PREVENTION; IMMUNOSTIMULATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
18
Recensione:
Indirizzi per estratti:
Citazione:
J.P. Collet et al., "STIMULATION OF NONSPECIFIC IMMUNITY TO REDUCE THE RISK OF RECURRENT INFECTIONS IN CHILDREN ATTENDING DAY-CARE-CENTERS", The Pediatric infectious disease journal, 12(8), 1993, pp. 648-652

Abstract

A randomized, double blind, placebo-controlled clinical trial was performed in 423 children attending day-care centers to assess whether stimulating nonspecific immunity would reduce the incidence of recurrentinfections. The drug used for the trial (Imocur(R)) is an extract obtained from eight different species of bacteria. At the end of the total follow-up period (3 months with treatment and 4.5 months without), the risk for greater-than-or-equal-to 4 episodes of upper respiratory infections was not significantly lower in the treated group than in theplacebo group (26.7% vs. 33.8%, relative risk, 0.79; 95% confidence interval, 0.59 to 1.06). In an exploratory analysis limited to the 3-month treatment period, however, we observed a 48% reduction in the riskof presenting greater-than-or-equal-to 3 episodes of upper respiratory infections: 9.5% vs. 18.3%, respectively, in the treatment group andthe placebo group (relative risk, 0.52; 95% confidence interval, 0.31to 0.86). Similar results were found for the risk of greater-than-or-equal-to 1 episode of gastroenteritis. We also observed a strong correlation between the drug efficacy and age; this observation is coherentwith the underlying pathophysiologic model in which the immune systemmatures with age.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 00:44:02